The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality
Open accessAbstract
BACKGROUND & AIMS Little is known about provider and health system factors that affect receipt of active therapy and outcomes of patients with hepatocellular carcinoma (HCC). We investigated patient, provider, and health system factors associated with receipt of active HCC therapy and overall survival. METHODS We performed a national, retrospective cohort study of all patients diagnosed with HCC from January 1, 2008 through December 31, 2010 (n = 3988) and followed through December 31 2014 who received care through the Veterans Administration (128 centers). Outcomes were receipt of active HCC therapy (liver transplantation, resection, local ablation, transarterial therapy, or sorafenib) and overall survival. RESULTS In adjusted analyses, receiving care at an academically affiliated Veterans Administration hospital (odds ratio [OR], 1.97; 95% confidence interval [CI], 1.60–2.41) or a multi-specialist evaluation (OR, 1.60; 95% CI, 1.15–2.21), but not review by a multidisciplinary tumor board (OR, 1.19; 95% CI, 0.98–1.46), was associated with a higher likelihood of receiving active HCC therapy. In time-varying Cox proportional hazards models, liver transplantation (hazard ratio [HR], 0.22; 95% CI, 0.16–0.31), liver resection (HR, 0.38; 95% CI, 0.28–0.52), ablative therapy (HR, 0.63; 95% CI, 0.52–0.76), and transarterial therapy (HR, 0.83; 95% CI, 0.74–0.92) were associated with reduced mortality. Subspecialist care by hepatologists (HR, 0.70; 95% CI, 0.63–0.78), medical oncologists (HR, 0.82; 95% CI, 0.74–0.91), or surgeons (HR, 0.79; 95% CI, 0.71–0.89) within 30 days of HCC diagnosis, and review by a multidisciplinary tumor board (HR, 0.83; 95% CI, 0.77–0.90), were associated with reduced mortality. CONCLUSIONS In a retrospective cohort study of almost 4000 patients with HCC cared for at VA centers, geographic, provider, and system differences in receipt of active HCC therapy are associated with patient survival. Multidisciplinary methods of care delivery for HCC should be prospectively evaluated and standardized to improve access to HCC therapy and optimize outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Ferlay, J., Shin, H., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010) · International Journal of Cancer · doi:10.1002/ijc.25516 · Cited by 21,293
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,853
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
DEYO, R. (1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90133-8 · Cited by 10,452
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,103
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Gloor, S., Jensen, K. O., Breitenstein, S., Binkert, C. A., Angst, E., & Hetzer, F. H. (2017) · Case Reports in Gastroenterology · doi:10.1159/000463378 · Cited by 5,370
A Model to Predict Survival in Patients With End–Stage Liver Disease
Kamath, P. S., Wiesner, R. H., Malinchoc, M., Kremers, W., Therneau, T. M., Kosberg, C. L., D'Amico, G., Dickson, R. E., & Kim, R. W. (2001) · Hepatology · doi:10.1053/jhep.2001.22172 · Cited by 4,975
Forner, A., Llovet, J. M., & Bruix, J. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61347-0 · Cited by 4,022
Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification
Llovet, J., Brú, C., & Bruix, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007122 · Cited by 3,805
Llovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
The burden of disease in older people and implications for health policy and practice
Prince, M. J., Wu, F., Guo, Y., Gutierrez Robledo, L. M., O'Donnell, M., Sullivan, R., & Yusuf, S. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61347-7 · Cited by 1,989
GLOBOCAN 2008 v1.2, Cancer incidence and mortality world-wide : IARC Cancer Base No. 10
Ferlay, J. (2010) · Medical Entomology and Zoology · Cited by 1,633
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
Park, J., Chen, M., Colombo, M., Roberts, L. R., Schwartz, M., Chen, P., Kudo, M., Johnson, P., Wagner, S., Orsini, L. S., et al. (2015) · Liver International · doi:10.1111/liv.12818 · Cited by 1,245
Epidemiology of Primary Liver Cancer
Bosch, F., Ribes, J., & Borràs, J. (1999) · Seminars in Liver Disease · doi:10.1055/s-2007-1007117 · Cited by 958
Bruix, J., Raoul, J.-L., Sherman, M., Mazzaferro, V., Bolondi, L., Craxi, A., Galle, P. R., Santoro, A., Beaugrand, M., Sangiovanni, A., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.06.014 · Cited by 822
Accuracy and completeness of mortality data in the Department of Veterans Affairs
Sohn, M.-W., Arnold, N., Maynard, C., & Hynes, D. M. (2006) · Population Health Metrics · doi:10.1186/1478-7954-4-2 · Cited by 542
Emerging trends in hepatocellular carcinoma incidence and mortality
Njei, B., Rotman, Y., Ditah, I., & Lim, J. K. (2015) · Hepatology · doi:10.1002/hep.27388 · Cited by 539
Cabibbo, G., Enea, M., Attanasio, M., Bruix, J., Craxì, A., & Cammà, C. (2010) · Hepatology · doi:10.1002/hep.23485 · Cited by 473
The Global Epidemiology of Hepatocellular Carcinoma: Present and Future
McGlynn, K. A., & London, W. T. (2011) · Clinics in Liver Disease · doi:10.1016/j.cld.2011.03.006 · Cited by 471
Cho, Y. K., Kim, J. K., Kim, M. Y., Rhim, H., & Han, J. K. (2009) · Hepatology · doi:10.1002/hep.22648 · Cited by 466
Altekruse, S. F., McGlynn, K. A., Dickie, L. A., & Kleiner, D. E. (2012) · Hepatology · doi:10.1002/hep.24710 · Cited by 262
Prognosis of untreated hepatocellular carcinoma
Giannini, E. G., Farinati, F., Ciccarese, F., Pecorelli, A., Rapaccini, G. L., Di Marco, M., Benvegnù, L., Caturelli, E., Zoli, M., Borzio, F., et al. (2015) · Hepatology · doi:10.1002/hep.27443 · Cited by 250
Yopp, A. C., Mansour, J. C., Beg, M. S., Arenas, J., Trimmer, C., Reddick, M., Pedrosa, I., Khatri, G., Yakoo, T., Meyer, J. J., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3413-8 · Cited by 242
Khalaf, N. I., Ying, J., Mittal, S., Temple, S., Kanwal, F., Davila, J. A., & El‐Serag, H. B. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.07.033 · Cited by 149
Chang, T. T., Sawhney, R., Monto, A., Davoren, J. B., Kirkland, J. G., Stewart, L., & Corvera, C. U. (2008) · HPB · doi:10.1080/13651820802356572 · Cited by 101
Stevenson, L. D., Ball, S. L., Haverhals, L. M., Aron, D. C., & Lowery, J. C. (2016) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x16677676 · Cited by 65
Hong, T., Gow, P. J., Fink, M. A., Dev, A. T., Roberts, S. K., Nicoll, A., Lubel, J. S., Kronborg, I., Arachchi, N., Ryan, M. C., et al. (2015) · Hepatology · doi:10.1002/hep.28267 · Cited by 63
Hyder, O. N., Dodson, R. M., Nathan, H., Herman, J. M., Cosgrove, D., Kamel, I. R., Geschwind, J.-F. H., & Pawlik, T. M. (2013) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2013.07.007 · Cited by 60
Assessing the Feasibility of a Virtual Tumor Board Program: A Case Study
Shea, C. M., Haynes‐Maslow, L., McIntyre, M., Weiner, B. J., Wheeler, S. B., Jacobs, S., Mayer, D. K., Young, M., & Shea, T. C. (2014) · Journal of Healthcare Management · doi:10.1097/00115514-201405000-00005 · Cited by 54
Improving Quality of Health Care for Patients With Cirrhosis
Kanwal, F., Volk, M. L., Singal, A. G., Angeli, P., & Talwalkar, J. A. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.10.029 · Cited by 36
Multispecialist Care and Mortality in Hepatocellular Carcinoma
Chirikov, V., Mullins, C. D., Hanna, N. N., Breunig, I. M., Seal, B. S., & Shaya, F. T. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000000 · Cited by 17
Cited by
A global view of hepatocellular carcinoma: trends, risk, prevention and management
Yang, J. D., Hainaut, P., Gores, G. J., Amadou, A., Plymoth, A., & Roberts, L. R. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0186-y · Cited by 4,228
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
Self-citationHepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., Bachini, M., Borad, M., Brown, D., Burgoyne, A., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0022 · Cited by 1,003
New advances in the diagnosis and management of hepatocellular carcinoma
Yang, J. D., & Heimbach, J. K. (2020) · BMJ · doi:10.1136/bmj.m3544 · Cited by 384
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Metadata
- Authors
- Serper, M., Taddei, T. H., Mehta, R., D’Addeo, K., Dai, F., Aytaman, A., Baytarian, M., Fox, R., Hunt, K., Goldberg, D. S., Valderrama, A., & Kaplan, D. E.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 152
- Issue
- 8
- Pages
- 1954-1964
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2594262320
- Cited by
- 265
- References
- 35
- FWCI
- 12.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.